Invest in Biosecure ID – Seed Round
🟢 Seed Round Open · $1.5M (£1.0M) Target · Early Investor Commitments Secured · SEIS/EIS Eligible Request investor pack →

Investor Relations · Seed Round 2025

Bringing speed and certainty to
forensic DNA testing

Biosecure ID delivers rapid, affordable, and accessible DNA testing solutions — empowering forensic laboratories worldwide with the speed and certainty that justice demands. Join us at the ground floor.

Request investor pack Explore the Vellixis Programme

Seed Round — open now

$1.5M (£1.0M)
Seed Round target
Early commitments secured
£30M
Serviceable entry market — Vellixis Nano forensic platform across US, EMEA, APJ & India
£1M
SEIS/EIS eligible — HMRC Advance Assurance confirmed. Significant tax relief for qualifying UK investors.
£2B
Addressable applied genomics market as the UDAP platform matures
<1 day
DNA profile turnaround with Vellixis vs 14 days today
↑80%
Increased sperm recovery demonstrated in interlaboratory studies
120M+
DNA profiles in global databases — doubling by 2035
5%
Of sexual assault victims currently report crimes — justice is failing

The Opportunity

A $25B market in transformation

The Applied Genetic Testing market is growing at double-digit CAGR. Forensic DNA laboratories worldwide are operating with legacy technology that is slow, costly, and unable to meet demand. Biosecure ID is positioned at the inflection point.

The bottleneck is preparation, not analysis

DNA science is not the constraint. The bottleneck is the sample preparation workflow that determines whether evidence reaches the analyst at all. On average, a DNA sample from a victim takes over 3 months to process. Samples can take 2 months just to reach the laboratory, risking evidence loss and compromising the chain of custody.

The Vellixis Programme directly addresses this — automating differential extraction with SpermX™ Nanofiber technology to deliver a DNA profile in under one day from sexual assault evidence.

Scaling from forensic casework, UDAP — Biosecure ID's Universal DNA Analysis Platform — targets a £2B applied genomics opportunity across human identification, animal health, agri genomics, and environmental testing.

Market expansion pathway

£30M
Vellixis Nano — forensic sexual assault casework entry. US, EMEA, APJ, India.
↓
£300M
Full Human ID market — databasing, DVI, rapid DNA at point of need, border control.
↓
£2B
Applied genomics — animal health, agri genomics, environmental testing via UDAP platform.

Use of Seed Funding

From proof of concept to product release

Biosecure ID has progressed from concept and prototyping to early internal validation. Functional prototypes have been tested across core forensic workflows with promising results. Seed funding accelerates the path to commercialisation.

1
Design-for-manufacture optimisation
Transitioning Vellixis prototypes from proof-of-concept to manufacturable formats. Supply chain readiness and inventory infrastructure.
2
Alpha and beta test site pilots
Deploying Vellixis at external forensic laboratory partner sites for real-world performance evaluation and validation data generation.
3
Quality and regulatory groundwork
Building the quality management system and regulatory dossier required for early commercialisation across target jurisdictions.
4
Go-to-market execution
Commercial team build-out, channel partner development, and growing the Vellixis install base across the £30M serviceable entry market.

Tax-efficient investing through SEIS & EIS

✓ HMRC Advance Assurance confirmed — up to £1M eligible

Biosecure ID has obtained HMRC Advance Assurance Approval for SEIS/EIS eligibility, providing qualifying UK investors with significant tax relief on investments of up to £1M.

SEIS and EIS are UK government-backed schemes designed to encourage investment in early-stage companies. They offer some of the most attractive investment tax reliefs available anywhere in the world.

HMRC SEIS guidance →
SEIS — up to 50% income tax relief
Invest up to £200,000 per tax year. Receive 50% income tax relief on the amount invested. Capital Gains Tax exemption on disposal after 3 years.
EIS — up to 30% income tax relief
Invest up to £2M per tax year (£10M for knowledge-intensive companies). 30% income tax relief. CGT deferral and loss relief available.
Loss relief protection
If the investment does not perform as expected, SEIS/EIS investors can claim loss relief against income tax, significantly reducing effective downside exposure.
Inheritance tax relief
Shares held for 2+ years may qualify for Business Property Relief, potentially reducing the inheritance tax liability on the investment.

Development Progress

Where we are and where we are going

Biosecure ID has made substantial progress from concept to validated prototypes. Seed funding accelerates the journey to commercial product release.

Completed
Concept & IP foundation
Core invention and IP strategy established. SpermX™ Nanofiber technology licensed from Innogenomics (US Patents). Early concept validation.
Completed
Prototype development
Multiple functional prototypes developed and tested (Platform-Agnostic Prototypes A & B) across core forensic and applied genomics workflows.
Completed
Early internal validation
Laboratory data and partner-led evaluations showing promising results in sample handling, recovery, and workflow efficiency vs existing approaches.
Completed
HMRC SEIS/EIS Advance Assurance
HMRC Advance Assurance confirmed for eligible investments up to £1M. Seed Round opened to investors.
Active — now
Seed Round fundraising
$1.5M (£1.0M) Seed Round open. Early commitments secured. Funding to support design-for-manufacture, pilot deployments, and go-to-market execution.
Next
Alpha & beta test sites
External forensic laboratory pilot deployments. Real-world performance data. Regulatory groundwork commences.
Planned
Commercial product release
Vellixis Nano commercialised across target jurisdictions. Install base growth.

Why invest now

Early-stage valuation
Seed-stage entry provides maximum equity upside as Vellixis progresses from prototype to commercial product.
Validated technology
SpermX™ underpinned by US Patents held by Innogenomics. Interlaboratory study published in Forensic Sciences journal (Dec 2023) demonstrating 80% increased recovery.
Large, growing market
Global forensic DNA market growing at double-digit CAGR. 120M+ profiles in databases — set to double by 2035. Hit rates approaching 50% in leading jurisdictions.
Government-backed tax efficiency
HMRC SEIS/EIS Advance Assurance confirmed. Up to 50% income tax relief through SEIS. Loss relief reduces effective downside exposure.
Platform, not just a product
Vellixis is the entry point into a universal platform targeting £2B in applied genomics — animal health, agri genomics, and environmental testing share the same technology stack.

Why Biosecure ID

Built on deep forensic expertise

A specialist team with scientific advisors across forensic science, materials science, and forensic genomics — operating from Alderley Park, one of Europe's leading life science campuses.

🏛️
UK-headquartered, global reach
Registered in Macclesfield. Laboratory operations at Alderley Park, Cheshire. Targeting US, EMEA, APJ, and India as primary markets.
📚
Published scientific validation
SpermX™ interlaboratory comparison published in Forensic Sciences (Dec 2023, DOI: 10.3390/forensicsci3040043) demonstrating 80% increased male DNA recovery.
🔐
IP-backed technology
SpermX™ Nanofiber protected by US Patents held by Innogenomics Technologies LLC. BSID building its own defensible IP portfolio through the Vellixis Programme.
🤝
Scientific advisory board
Advisors include experts in forensic science & ISO standards, nanofiber materials science, Additive Manufacturing, Smart surface chemistry, Assay Design and forensic genomics. Strong commercial partnerships across the value chain.
🌍
Social impact mission
Closing the justice gap for sexual assault victims worldwide. Addressing the structural barriers — speed, cost, complexity — that prevent DNA evidence from reaching analysts.
⚡
UK Innovation Ecosystem
Actively Applying for Competitive UKRI Grants - Targeting TRL 6 across all Vellixis sub-components within 18-month incubation period.

Join us in our Seed Round

Investor and fund managers — request our investor pack to learn more, review our documentation, and schedule a conversation with the team.

Request investor pack Full investor portal →

Important — Investment Disclaimer & Confidentiality

Any discussion of potential investments is for informational purposes only and does not constitute an offer, solicitation, or recommendation to invest. Investments involve risk, including loss of capital. Tax relief eligibility depends on individual circumstances and may be subject to change. By making an investment enquiry, you agree that all information shared is confidential and may not be disclosed to third parties without prior written consent from Biosecure ID. Any ideas, materials, or information shared are the intellectual property of Biosecure ID unless otherwise agreed in writing. Your personal information will be used solely to manage investment enquiries in accordance with our Privacy Policy. © 2025, Biosecure ID Limited. All rights reserved. Companies House No. 15571838.